A Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers
This study has been completed.
Sponsor:
Novartis
Information provided by:
Novartis
ClinicalTrials.gov Identifier:
NCT00134992
First received: August 24, 2005
Last updated: June 7, 2006
Last verified: June 2006
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this trial was to confirm the tolerability of prednisolone acetate 0.5% eye drops by testing the hypothesis that the ocular safety and tolerability of prednisolone acetate 0.5% eye drops are equivalent to vehicle. Thus healthy volunteers have been selected and have been treated by using a crossover design.
| Condition | Intervention | Phase |
|---|---|---|
|
Healthy |
Drug: Prednisolone acetate |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Crossover Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Single-Center, Randomized, Double Masked, Two-Period Cross-Over, Three Days Per Period, Phase IV Study to Compare Ocular Safety and Tolerability of Prednisolone Acetate 0.5% Eye Drops Versus Vehicle in Healthy Volunteers |
Resource links provided by NLM:
MedlinePlus related topics:
Edema
Drug Information available for:
Prednisolone
Prednisolone acetate
Methylprednisolone acetate
Methylprednisolone
Prednisolone sodium phosphate
Prednisolone phosphate
Tetrahydrozoline hydrochloride
Prednisolone sodium succinate
Methylprednisolone sodium succinate
Boric acid
U.S. FDA Resources
Further study details as provided by Novartis:
Primary Outcome Measures:
- Tolerability of the trial drug by evaluating the overall sum-score of the slit lamp examination built by adding up the scores for conjunctival hyperemia, conjunctival edema, palpebral hyperemia, lid edema and corneal edema
Secondary Outcome Measures:
- Tolerability of the trial drug
- and the frequency, severity and relationship to study medication of all adverse events occurring during the course of the study.
| Estimated Enrollment: | 30 |
| Study Start Date: | August 2004 |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Healthy subjects of either gender, 18 years or older, who were able to give an informed consent
- A score for ocular discomfort of 0-20 mm on the visual analogue scale (VAS) prior to treatment
Exclusion Criteria:
- Known hypersensitivity to any of the constituents of the medications
- Known corticosteroid responder (elevation of intraocular pressure [IOP])
- Known allergic disposition (e.g. hay fever)
- Need of ocular antiallergic treatment
- Wearing of contact lenses
- Any kind of current eye disease (e.g. dry eye)
- Any kind of concomitant ocular treatment
- Any injury or infection in either eye during the last 3 months prior to the first application
- Any medication taken within the last 28 days prior to the first application, except hormonal contraceptives
- Concomitant or previous treatment with antihistamines within a week prior to enrolment
- Pregnant or breast feeding women
- Participation in another clinical study within 4 weeks prior to enrolment
- Hematological diseases such as aplastic anemia, panmyelopathy, or hemolytic icterus; with severe dysfunction of the liver.
- Any medical or laboratory condition which, in the Investigator’s opinion, would preclude the participant from adhering to the protocol or completing the trial per protocol
- Subjects with history of malignancy of any organ system, treated or untreated, within the past five years, whether or not evidence of local recurrence or metastases exist, are excluded, with the exception of localized basal cell carcinoma of the skin
Contacts and Locations
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00134992 History of Changes |
| Other Study ID Numbers: | CULT 491 DE 02 |
| Study First Received: | August 24, 2005 |
| Last Updated: | June 7, 2006 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Keywords provided by Novartis:
|
Prednisolone acetate eye drops tolerability Healthy volunteers |
Additional relevant MeSH terms:
|
Tetrahydrozoline Methylprednisolone Methylprednisolone acetate Prednisolone acetate Prednisolone Methylprednisolone Hemisuccinate Prednisolone hemisuccinate Prednisolone phosphate Nasal Decongestants Vasoconstrictor Agents Cardiovascular Agents Therapeutic Uses Pharmacologic Actions Respiratory System Agents Sympathomimetics |
Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Inflammatory Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Antiemetics Central Nervous System Agents Gastrointestinal Agents Neuroprotective Agents Protective Agents |
ClinicalTrials.gov processed this record on May 16, 2013